The antifungal agent Amphotericin B is highly effective against a wide range of deadly fungi and resistance is rare, even after decades of use. But it comes with a virtual guarantee of kidney damage, earning it the nickname “Ampho-terrible.”   

Now, a better alternative might be on the way. Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., a chemistry professor and researcher at the University of Illinois and the founder of antifungal startup Sfunga Therapeutics, to get the story behind the new drug’s design, its path to the clinic and how it could influence the next generation of antimicrobials.

To learn more about the topics in this episode: 
Potent new drug has all the power of nature's strongest antibiotic, without the toxicity

The antifungal agent Amphotericin B is highly effective against a wide range of deadly fungi and resistance is rare, even after decades of use. But it comes with a virtual guarantee of kidney damage, earning it the nickname “Ampho-terrible.”   
Now, a better alternative might be on the way. Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., a chemistry professor and researcher at the University of Illinois and the founder of antifungal startup Sfunga Therapeutics, to get the story behind the new drug’s design, its path to the clinic and how it could influence the next generation of antimicrobials.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/research/potent-new-antifungal-has-all-power-amphotericin-b-without-toxicity" data-cke-saved-href="https://www.fiercebiotech.com/research/potent-new-antifungal-has-all-power-amphotericin-b-without-toxicity">Potent new drug has all the power of nature's strongest antibiotic, without the toxicity</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement